Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Cancer Research / Development of a 68Gallium-Labeled D-Peptide PET…
JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Cancer Research
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
 

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Article DOI: 10.3791/65047-v • 09:06 min • February 3rd, 2023
February 3rd, 2023 •
*1, *2, 1, 2, 2, 4, *2,3, *3, *1, *2
1Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 2State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 3Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
* These authors contributed equally

Chapters

Summary
Automatic Translation

This study developed a noninvasive and real-time method to evaluate the distribution of programmed death-ligand 1 in the whole body, based on positron emission tomographic imaging of [68Ga] D-dodecapeptide antagonist. This technique has advantages over conventional immunohistochemistry and improves the efficiency of identifying appropriate patients who will benefit from immune checkpoint blockade therapy.

Tags

Keywords: 68Gallium D-peptide PET Tracer PDL-1 Expression Radiolabeling HPLC Serum Stability Cell Binding
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter